Sugi Predict

Sugi Predict / Compounds / SCHEMBL721635

SCHEMBL721635

SCHEMBL721635

C[C@]1(OC(=O)c2ccccc2)[C@H](OC(=O)c2ccccc2)O[C@H](COC(=O)c2ccccc2)[C@H]1OC(=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.49
▸ NPC1 O15118 1/20 0.42
▸ MAPT P10636 1/20 0.41
▸ POLB P06746 3/20 0.41
▸ GAA P10253 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ CHRNB2 P17787 1/20 0.40
▸ CHRNA5 P30532 1/20 0.40
▸ CHRNA7 P36544 1/20 0.40
▸ CHRNA4 P43681 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ SLC6A2 P23975 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CES2 O00748 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13857762 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL13941468 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL14037391 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL14571165 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL14853799 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL882168 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL19276651 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL21418908 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL21418911 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL1287234 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2319853-B1 Process for the production of 2'-branched nucleosides IDENIX PHARMACEUTICALS INC (US) 2014-03-12 — — EP claimed
EP-2319853-A1 Process for the production of 2'-branched nucleosides Idenix (Cayman) Limited (KY) 2011-05-11 — — EP claimed
US-7598373-B2 Process for the production of 2-C-methyl-D-ribonolactone IDENIX PHARMACEUTICALS, INC. (US) 2009-10-06 — — US claimed
EP-1585529-A4 PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES IDENIX CAYMAN LTD (KY) 2008-05-28 — — EP claimed
EP-1585529-A2 PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES Idenix (Cayman) Limited (KY) 2005-10-19 — — EP claimed
US-20050020825-A1 Process for the production of 2'-branched nucleosides IDENIX PHARMACEUTICALS LLC 2005-01-27 — — US claimed
WO-2004052899-A2 PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES IDENIX (CAYMAN) LIMITED (KY) 2004-06-24 — — WO claimed
CN-118139868-A Orally bioavailable nucleoside analogs 维纳拓尔斯制药公司 2024-06-04 — — CN disclosed
EP-3013340-B9 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN PHARMACEUTICALS INC (US) 2023-10-04 — — EP disclosed
EP-3399984-B1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES INC (US) 2023-09-06 — — EP disclosed
US-20230233593-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS VenatoRx Pharmaceuticals, Inc. 2023-07-27 — — US disclosed
EP-3013340-B1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN BIOPHARMA INC (US) 2023-06-07 — — EP disclosed
US-11667662-B2 Modulators of 5′-nucleotidase, ecto and the use thereof ARCUS BIOSCIENCES, INC. (US) 2023-06-06 — — US disclosed
WO-2004069851-A1 PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES INALCO S.P.A. (IT) 2004-08-19 — — WO disclosed
US-20040158059-A1 Process for the preparation of ribofuranose derivatives INALCO S.P.A. (IT) 2004-08-12 — — US disclosed
WO-2004052899-A2 PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES IDENIX (CAYMAN) LIMITED (KY) 2004-06-24 — — WO disclosed
US-20040077587-A1 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections IDENIX PHARMACEUTICALS, INC. 2004-04-22 — — US disclosed
WO-2004002422-A2 2’-C-METHYL-3’-O-L-VALINE ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS IDENIX (CAYMAN) LIMITED (KY) 2004-01-08 — — WO disclosed
WO-2004003000-A2 1’-, 2'- AND 3'- MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS IDENIX (CAYMAN) LIMITED (KY) 2004-01-08 — — WO disclosed
WO-2003093290-A2 NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION GENELABS TECHNOLOGIES, INC. (US) 2003-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077587-A1 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections NSUN2, BCDIN3D, METTL16 ALDH1A1 2796/4885NPC1 3047/4885MAPT 3751/4885
US-11667662-B2 Modulators of 5′-nucleotidase, ecto and the use thereof ENTPD5, NT5C2, NT5E ALDH1A1 1423/4885NPC1 1791/4885MAPT 4281/4885
US-20050020825-A1 Process for the production of 2'-branched nucleosides RNGTT, MTAP, NSUN2 ALDH1A1 2027/4885NPC1 2308/4885MAPT 3665/4885
US-20230233593-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS SLC29A2, SLC29A1, PNP ALDH1A1 2219/4885NPC1 67/4885MAPT 2576/4885
US-20040158059-A1 Process for the preparation of ribofuranose derivatives RNGTT, RPIA, MRM1 ALDH1A1 960/4885NPC1 2950/4885MAPT 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.